Ultraslow thrombolytic therapy: A novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow PROMETEE trial

ÖZKAN, MEHMET; GÜNDÜZ, SABAHATTİN; GÜRSOY, OZAN; KARAKOYUN, SÜLEYMAN; ASTARCIOĞLU, MEHMET; KALÇIK, MACİT; AYKAN, AHMET; ÇAKAL, BEYTULLAH; BAYRAM, ZÜBEYDE; OĞUZ, ALİ; ERTÜRK, EMRE; YESİN, MAHMUT; GÖKDENİZ, TAYYAR; Duran, Nilufer; YILDIZ, MUSTAFA; ESEN, ALİ

doi:10.1016/j.ahj.2015.04.025

Ultraslow thrombolytic therapy: A novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow PROMETEE trial

ÖZKAN M., GÜNDÜZ S., GÜRSOY O. M., KARAKOYUN S., ASTARCIOĞLU M. A., KALÇIK M., ...Daha Fazla

AMERICAN HEART JOURNAL, cilt.170, sa.2, ss.409-419, 2015 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 170 Sayı: 2
Basım Tarihi: 2015
Doi Numarası: 10.1016/j.ahj.2015.04.025
Dergi Adı: AMERICAN HEART JOURNAL
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.409-419
Kütahya Sağlık Bilimleri Üniversitesi Adresli: Hayır

Özet

Background Low-dose (25 mg), slow infusion (6 hours) of tissue-type plasminogen activator (t-PA) with repetition as needed has been shown to provide effective and safer thrombolysis in patients with prosthetic valve thrombosis (PVT). Further prolonging the infusion time may be rational with regard to reducing complication rates without reducing success rates. We aimed to investigate the efficacy and safety of ultraslow (25 hours) infusion of low-dose (25 mg) alteplase (t-PA) for PVT.